AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00896974 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Retinoid 9cUAB30
Description: Given orally
Study NCT02020278 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tolvaptan
Description: Tolvaptan 3.75-, 7.5-, 15-, and 30-mg spray-dried tablets. Dosage: Depending on age and weight, Tablet (3.75 mg - 60 mg daily). Frequency: Once daily.~Duration: Participants may be eligible to receive short-term or long-term optional tolvaptan treatment at any time during their participation in the trial, with one or more treatment cycles over a 6-month period.
Study NCT04970303 — intervention group
Intervention type: DRUG
Intervention: Methylphenidate
Description: Retina or Concerta
Study NCT01491451 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: rhBMP-2/ACS/INTERFIX™
Description: INTERFIX™ device containing recombinant human Bone Morphogenetic Protein-2 (rhBMP-2) and the absorbable collagen sponge (ACS) carrier.
Study NCT01491451 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Autogenous bone/INTERFIX™
Description: INTERFIX™ device containing autogenous bone taken from the patient's iliac crest.
Study NCT04685512 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tenofovir disoproxil and emtricitabine
Description: Experimental drugs administration of 7-day short course TDF/FTC
Study NCT01793493 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cognitive stimulation
Description: Participants are pooled in small groups (6-8 individuals). Each group participates to ten twice weekly meetings. Each CS session is run by one trained operator. One observer participates to the sessions to guarantee homogeneity between different operators. Exercises are structured with an increasing cognitive complexity and are tailored to the characteristics of the group.~Meetings (each lasting about 2 hours) have a common structure:~* body awakening (10 minutes)~* cognitive stimulation (1 hour and a half) scheduled as follow:~  * temporospatial orientation~ * attentional abilities~ * one of the following cognitive areas: language, executive functions, verbal and visual memory (encoding, consolidation, retrieval)
Study NCT01793493 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sanitary education
Description: Participants attend two weekly meetings (for a total of 3 hours) focused on lifestyle education and brain functioning.
Study NCT00981487 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ondansetron
Description: 24 mg one time
Study NCT00981487 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ondansetron
Description: 24 mg, on time in the am
Study NCT03730207 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Xpede™ Bone Cement
Description: Xpede™ Bone Cement will be injected into vertebral body via percutaneous Vertebroplasty or Kyphoplasty to stabilize the fractured vertebral body by filling the bony trabeculae.
Study NCT03730207 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Mendec Spine Bone Cement
Description: Mendec Spine Bone Cement will be injected into vertebral body via percutaneous Vertebroplasty or Kyphoplasty to stabilize the fractured vertebral body by filling the bony trabeculae.
Study NCT02951754 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Immediate-release Methylphenidate
Description: Standard initial dose of 10 mg, twice or three times daily with doses increasing weekly until symptom control or occurrence of limiting adverse effects
Study NCT03624192 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RECELL® Autologous Cell Harvesting Device
Description: Application of RES prepared using the RECELL® Autologous Cell Harvesting Device along with Telfa™ Clear primary and Xeroform™ secondary wound dressings
Study NCT03624192 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Telfa™ Clear and Xeroform™ dressings
Description: Telfa™ Clear and Xeroform™ dressings
Study NCT00725257 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mediterranean diet
Description: The recommended composition of the dietary regimen was as follows: Carbohydrate 40 to 50%, protein 15 to 20%; fat 30 to 40%; saturated fat less than 10%.
Study NCT00725257 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low-fat diet
Description: The recommended composition of the dietary regimen was as follows: Fat less than 30%; carbohydrate 50 to 60%, protein 15 to 20%; saturated fat less than 10%.
Study NCT02078700 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The early palliative care programme
Description: The intervention consists of an early integration of a palliative care programme with the standard care performed by the oncologists-pneumologists that are following the cancer patients. The intervention will be delivered by the specialised Palliative Care Unit (PCU) of the hospital. Each patient meets the professionals of the PCU by 30 days by cancer diagnosis and at least monthly thereafter in the outpatint settings.
Study NCT01358461 — intervention group
Intervention type: BIOLOGICAL
Intervention: Blood sampling
Description: Blood sampling
Study NCT01358461 — intervention group
Intervention type: OTHER
Intervention: ECG-Holter 24 h tape and sino-carotid stimulation test
Description: ECG-Holter 24 h tape and sino-carotid stimulation test
Study NCT03135015 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Placebo capsules
Description: 250ml water with 16 x 250mg placebo capsules
Study NCT03135015 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: 2g capsules
Description: 250ml water with 8 x 250mg capsules containing Axulin powder plus 8 x 250mg placebo capsules
Study NCT03135015 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: 4g capsules
Description: 250ml water with 16 x 250mg capsules containing Axulin powder
Study NCT03135015 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Water Control
Description: 250ml water
Study NCT01428622 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: BI54903
Description: ethanolic solution
Study NCT01428622 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI54903
Description: ethanolic solution
Study NCT01428622 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BI54903
Description: ethanolic solution
Study NCT03135015 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: 2g tablets
Description: 250ml water with 2 x 1g tablets containing Axulin powder
Study NCT03135015 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: 4g tablets
Description: 250ml water with 4 x 1g tablets containing Axulin powder
Study NCT03117192 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zinc Sulfate
Description: Zinc supplementation in syrup form
Study NCT03117192 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sucrose Syrup
Description: Sucrose as placebo, with same taste and consistency as zinc
Study NCT03858621 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fentanyl NOL guided
Description: Intervention is NOL monitoring in this group that will help to guide intravenous administration of fentanyl during surgery.
Study NCT00555711 — intervention group
Intervention type: DEVICE
Intervention: Modulated Imaging
Description: Modulated Imaging
Study NCT03481582 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitroglycerin
Description: (nitrodermal®) 5 mg (patch)as a source of Nitric oxide from 2nd day of cycle till maturation of the follicles ≥ 18 mm just for one cycle.
Study NCT03481582 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Three dimensional power doppler
Description: Once the follicle reached ≥18 mm 3D power Doppler will be used to assess the uterine and subendometrial blood flow
Study NCT03481582 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Three dimensional power doppler
Description: Once the follicle reached ≥18 mm 3D power Doppler will be used to assess the uterine and subendometrial blood flow
Study NCT00560820 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deferasirox
Description: 30 mg/kg/day
Study NCT03788343 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Phenylalanine
Description: The study product Phenylalanine, a dietary supplement, is authorized in Switzerland, but not designated for this patient group.
Study NCT03788343 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules are indistinguishable in their appearance from Phe capsules
Study NCT02548169 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: DC Vaccine + Standard of Care Chemotherapy
Description: 4 doses of DC vaccine at 2 weeks interval, combined with either:~* Standard of care neoadjuvant folinic acid, oxaliplatin, irinotecan and 5- Fluorouracil (5FU) (FOLFIRINOX) regimen alone (6 cycles)~* FOLRIRINOX regimen followed by 5-FU chemoradiation or Gemcitabine Chemoradiation~* Gemcitabine + nab-paclitaxel~The first vaccination will include one intradermal injection of 100 μL at 15 x106 cells/mL in the upper thigh and one subcutaneous injection of 1 mL (15 x 106 cells/mL) .~The participants will receive 3 additional subcutaneous vaccinations, each injection of 1 mL at 15 x 106 cells/mL, at 2 weeks interval, on Day 2 of study weeks 3, 5 and 7.~Participants will receive 2 booster DC vaccinations subcutaneously of 1 mL at 15x106 cells/mL.
Study NCT00876330 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinical Decision Support for Hypertension
Description: Clinical decision support alerts for antihypertensive therapy
Study NCT00876330 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Automated Telephone Outreach for Antihypertensive Therapy
Description: Automated Telephone Outreach to patients for antihypertensive medication therapy.
Study NCT00876330 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinical Decision Support for Lipid-lowering Therapy
Description: Clinical Decision Support alerts for Lipid-lowering medication therapy.
Study NCT00876330 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Automated Telephone Outreach for Lipid-lowering Therapy
Description: Automated telephone outreach to patients for Lipid-lowering medication therapy.
Study NCT01892956 — intervention group
Intervention type: OTHER
Intervention: Nutritional intervention
Description: 2 dietary interventions~1. personalized diet based on algorithm predictions of glucose response to foods~2. Mediterranean-style diet
Study NCT01226927 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Automated intermittent bolus
Description: Automated intermittent bolus delivery method of 0.2% ropivacaine at 5 mL every 30 minutes with a basal infusion of 0.1 mL/hr.
Study NCT02934399 — intervention group
Intervention type: OTHER
Intervention: 27 hour subcutaneous fluid sampling
Description: One hour prior to the microdialysis catheter insertion the participants will be asked to receive a local anaesthetic on the injection site for the microdialysis catheter. Lignocaine 1% will be injected subcutaneously at a localised site on the abdomen covering a horizontal area of about 5cm after a brief acclimatisation period at the hospital.~A sterile linear catheter will be inserted using aseptic precautions at the anaesthetised site on the abdomen. The catheter is connected at one end to the microdialysis pump, and at the other end to the automated collection device. Subcutaneous tissue microdialysis samples will be collected regularly for the duration of the sampling period (27 hours).
Study NCT02713828 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phase I: Glembatumumab Vedotin
Description: Escalation Phase: Three to 6 patients will be enrolled in each dose cohort based on a standard Phase I dose escalation scheme. For the dose-escalation, the starting dose of glembatumumab vedotin will be 1.9 mg/kg q3w (Cohort 1). In the event of ≥ 2 DLTs, the dose will de-escalate to Cohort -1 (1.3 mg/kg).~Dose escalation from Cohort 1 to Cohort 2 (2.2 mg/kg) may proceed if three patients in Cohort 1 complete the DLT observation period with 0 DLTs, or if six patients in Cohort 1 complete the DLT observation period with 0 or 1 DLTs.
Study NCT02713828 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phase II: Glembatumumab Vedotin
Description: In Stage 1, approximately 20 eligible, treated patients will be enrolled. If ≥ 2 patients achieve a tumor response (Partial Response \[PR\] or Complete Response \[CR\]), an additional 15 eligible, treated patients will be enrolled in Stage 2, for a maximum total of 35 eligible, treated patients.
Study NCT02669992 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Stapled or Hand-sewn anastomosis
Description: Randomization between stapled or hand-sewn anastomosis
Study NCT02669992 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stapled or Hand-sewn anastomosis
Description: Randomization between stapled or hand-sewn anastomosis
Study NCT02669992 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Mesh or suture stoma site closure
Description: Randomization between suture or Mesh closure of the stoma site
Study NCT02669992 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Mesh or suture stoma site closure
Description: Randomization between suture or Mesh closure of the stoma site
Study NCT03192761 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ACL reconstruction hamstrings
Description: HG reconstruction is performed according to the standard procedure of the department:~A double semi-Tendinosus and gracillis graft is used. Placement of the bony tunnels is anatomical, and the femoral tunnel is positioned through the antero-medial portal. Fixation proximally is by CL-endobutton and at the tibia by Intrafix sheet and screw
Study NCT03192761 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ACL reconstruction patella tendon
Description: PTBG reconstruction is performed according to the standard procedure of the department:~A bone patella tendon bone graft of 1 cm width from the midportion of the tendon is used. Placement of the bony tunnels is anatomical, the femoral being positioned through the antero-medial portal. Fixation proximally and distally is by interference screws.
Study NCT03192761 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ACL reconstruction iliotibial tract
Description: TIFLG reconstruction is performed as follows:~The TIFL graft is harvested using two lateral incisions. The graft is left attached to the distal iliotibial tract. Placement of the bony tunnels is anatomical, the femoral being drilled outside-in. The tibial drill tunnel is made by retrograde drilling 20 mm, leaving cortical bone at the distal end of the tunnel. Fixation distally is by CL-endobutton or interference screw and on femur by an interference screw outside-in.
Study NCT03813914 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Sineos
Description: glycyrrhizic acid 38 mg + Cinnamomum Zeylanicum 150 mg + corosolic acid 480 mcg 2 pills per day
Study NCT03813914 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Sineos
Description: glycyrrhizic acid 38 mg + Cinnamomum Zeylanicum 150 mg + corosolic acid 480 mcg 2 pills per day
Study NCT02812927 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Edelvaiss Multiline-8
Description: Optimised infusion line
Study NCT02812927 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Standard infusion line
Study NCT03052595 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Oral glucose tolerance test
Description: Oral glucose tolerance test to measure glucose and insulin concentrations after oral glucose load
Study NCT03052595 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Testing of autonomous nervous system function
Description: Autonomous nervous system function will be assessed using a battery of tests (orthostasis, Valsalva manoeuvre, heart rate variability recording, blood hormone levels, ect.)
Study NCT03052595 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Stroop test
Description: Stroop test will be used to test cognitive function
Study NCT00565123 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.5% levofloxacin eye drops
Description: 0.5% levofloxacin eye drops three times daily to each eye for 5 days
Study NCT00565123 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.5% levofloxacin eye drops
Description: 0.5% levofloxacin eye drops 2 hours on days 1 and 2, and then every 4 hours on days 3-5 (up to 4 times per day)
Study NCT04359485 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Glycolic acids peel 70%
Description: Glycolic acid peel 70% applied in 3 coats medium depth
Study NCT04359485 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Sodium chloride
Study NCT01092910 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Esteem Totally Implantable Hearing System
Description: The Esteem System is a totally implantable hearing system designed to improve hearing in adult subjects suffering from mild to severe hearing loss that is sensorineural in origin.
Study NCT01340573 — intervention group
Intervention type: DRUG
Intervention: PegIntron Pen
Description: Peginterferon alfa-2b, 1.5 microgram/kg each week, administered subcutaneously.
Study NCT01340573 — intervention group
Intervention type: DRUG
Intervention: Ribavirin
Description: Dose is based on body weight. Each tablet of ribavirin is 200mg, and given by oral administration. Participants with body weight of \<65 kg were administered 800 mg of ribavirin daily, body weight of 65 kg-85 kg received 1000 mg daily, and participants with a body weight of >85 kg received 1200 mg of ribavirin daily.
Study NCT03263338 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mobile Sleep and Growth Study
Description: The intervention is designed to test if sleep tips delivered by text messages can aid with reaching time in bed targets. And if additional motivational text messages can further aide with reaching time in bed targets.
Study NCT03263338 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mobile Sleep and Growth Study
Description: The intervention is designed to test if sleep tips delivered by text messages can aid with reaching time in bed targets. And if additional motivational text messages can further aide with reaching time in bed targets.
Study NCT01265927 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GRN163L in combination with trastuzumab
Description: GRN163L will be administered in escalating dose cohorts on Day 1 of each 21-day cycle prior to trastuzumab infusion. Trastuzumab will be a administered day 1 of each 21-day cycle after GRN163L. There will be a 30 minute observation period between the end of the GRN163L infusion and the beginning of the trastuzumab infusion.
Study NCT03214406 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arm & Hammer Advance White Brilliant Sparkle (Test product)
Description: 20% sodium bicarbonate
Study NCT03214406 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Crest Cavity Protection Regular Toothpaste (Negative Control)
Description: Negative control
Study NCT00492336 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rasagiline (Pharmacodynamics)
Description: Rasagiline 1 mg/day for 12 weeks
Study NCT00492336 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 1 tablet each day
Study NCT01418079 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: O2 MedTech cerebral oximeter (Oxygen desaturation)
Description: Reduction in blood oxygen saturation by sequential reduction in inspired gas composition. Steps are of 6 minutes duration with reduction in pulse oximeter oxygen saturation from 100 to 70%.
Study NCT04310566 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: JJVC Investigational Multifocal Contact Lens (senofilcon A c3)
Description: TEST
Study NCT04310566 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dailies Total 1® Multifocal Contact Lens
Description: CONTROL
Study NCT03227666 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: The intervention group will perform three supervised group training sessions a week, consisting of 30 minutes of balance training for 4 weeks.
Study NCT04165499 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Combination of Plant Extracts (BSL_EP026)
Description: Each participant will consume 2 capsules daily, in the morning and in the evening.
Study NCT04165499 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Each participant will consume 2 capsules daily, in the morning and in the evening.
Study NCT04067414 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BZ019
Description: Subjects will be enrolled in three dose-groups:~Dose 1: 1×10\^6/kg CAR+ cells; Dose 2: 3×10\^6/kg CAR+ cells; Dose 3: 6×10\^6/kg CAR+ cells.
Study NCT03167021 — intervention group
Intervention type: OTHER
Intervention: Survey
Description: This observational and transversal study will be conducted as a survey using the REDCap software and the response to this survey will be done online, in real time, with an automatic, secure and centralized data collection (CHU Clermont-Ferrand).
Study NCT00429169 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paroxetine
Description: Dosage will be 25 mg every day for 2 weeks, then 37.5 mg every day for 2 weeks, and then optional increase to 50 mg every day for the remainder of treatment.
Study NCT00429169 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupropion
Description: Dosage will be 150 mg every day for 2 weeks, then 300 mg every day for 2 weeks, and then optional increase to 450 mg every day for the remainder of treatment.
Study NCT04443309 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab
Description: Camrelizumab 200mg,iv,d1,q2w